AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
The market is within reach
Updates
04/02/19 Financing i...Some extra non-dilutive financing
24/12/18 EPSThe new number of shares has been adju...
24/12/18 NAVThe lower NAV per share stems from the...
24/12/18 DCFThe lower NAV per share stems from the...
21/12/18 LatestSuccess of the capital increase
29/11/18 TargetOur target price is revised downward on t...
29/11/18 EPSOur forecasts have not changed. The hig...
29/11/18 NAVOur NAV valuation is adjusted one the on...
29/11/18 DCFOur forecasts remain unchanged. The hig...
28/11/18 Financing i...A €3.9m capital increase
22/11/18 LatestExcellent news: production has resumed
23/10/18 Other newsBond conversion
03/10/18 EPSOur EPS forecasts only move marginally i...
03/10/18 NAVOur SOTP valuation goes down in line wit...
03/10/18 DCFOur DCF valuation goes quite substantial...
27/09/18 EarningsH1 18: insignificant; some more time nee...
05/09/18 EPSWe have fine-tuned our numbers in the b...
05/09/18 NAVWe have adjusted our numbers to take in...
05/09/18 DCFOur DCF valuation goes up quite signific...
13/07/18 Financing i...A convertible bond and potential options f...
17/05/18 LatestBusiness update
22/03/18 EarningsOn its way to reach the market…
14/02/18 Financing i...A convertible bond and options for existin...
03/02/18 Other newsOrphan disease status for Zeneo® Midaz...
11/12/17 Other newsUpdate on the company’s activities
25/09/17 EarningsH1 17: a new NTE in the pipeline...and fu...
06/04/17 Financing i...The capital increase was successful
14/03/17 EPSWe have not changed our assumptions a...
14/03/17 NAVThe SOTP valuation is only down on the ...
14/03/17 DCFOur DCF goes down on the increased nu...
13/03/17 EarningsFY16 results - untelling (as expected) an...
24/11/16 TargetOur target price goes down, mainly due t...
24/11/16 EPSOur EPS goes marginally down for FY17,...
24/11/16 NAVOur SOTP valuation also goes down, sin...
24/11/16 DCFWe have revised our forecasts, based on ...
23/11/16 StrategyA strategic review….and a few questions
20/09/16 EarningsH1 16 results: not very telling as expected
29/08/16 Other newsWhen apparent threats are also opportuni...
Target
Upside 563%
Price (€) 1.56
Market Cap (€M) 14.5
Perf. 1W: 29.1%
Perf. 1M: 31.3%
Perf. 3M: 18.3%
Perf Ytd: 29.5%
10 day relative perf. to stoxx600: 9.63%
20 day relative perf. to stoxx600: 25.3%
Overview
Value
Equity Risk
Governance
Ranking
Best
Crossject
Pharma
Worst